Danaher posts strong Q2; Masimo close boosts 2026 EPS guidance
Jul 21, 2026, 6:05 AM EDT2 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Solid Q2 beat, EPS uplift, and Masimo closing imply near-term upside to the stock; the new core metric and tariff-exclusion guidance reduce noise around volatile respiratory testing, supporting a higher multiple. Historical analogs show Danaher stock reacting positively to earnings beats and successful acquisitions that meaningfully raise mid-term earnings trajectory.
AI summary
What happened, with direct paths to the underlying reporting
Danaher reported a solid Q2 with revenue at $6.3B and net earnings of $870M ($1.23 per share), up 60% YoY, along with an 8% rise in non-GAAP EPS to $1.94. Core revenue rose 3.0% (4.5% excluding respiratory testing), and operating cash flow was $1.5B. The Masimo acquisition has closed earlier than expected, enabling a higher full-year EPS target of $8.45–$8.60, while the company also updates guidance for 3Q and full-year core sales growth. A new non-GAAP metric, core sales excluding respiratory testing, was introduced to better reflect underlying growth, and tariff refunds will be excluded from core starting in Q3 2026.
Q2 2026 earnings: net $870M, $1.23 per diluted share, up 60% YoY.
Revenue $6.3B, up 5.5% YoY; Non-GAAP core revenue +3.0% (ex respiratory +4.5%).
Outlook: 3Q core revenue +2.0% to 3.0%; full year core +3% to 4%.
New metric: Core sales excluding respiratory testing; tariff refunds to be excluded from core starting Q3 2026.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Danaher raised its annual profit forecast on Tuesday, signaling earnings strength, but trimmed its core revenue growth outlook and posted weaker-than-expected biotechnology revenu…
Danaher Corporation has priced a €2.98 billion senior notes offering to finance its acquisition of Masimo Corporation. This capital raise could strengthen Danaher's balance sheet…
Danaher Corporation reported solid Q1 2026 results, with net earnings of $1.0 billion and a 9.5% increase in adjusted EPS to $2.06. The company also raised its full-year EPS guida…
Danaher Corporation reported solid Q1 2026 results with a 9.5% growth in non-GAAP adjusted earnings per share and a 3.5% increase in revenue to $6 billion. The company also announ…
